Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma

Ikeda, Masafumi; Maeda, Seishi; Ashihara, Hiroshi; Nagahama, Hiroyasu; Tanaka, Motohiko; Sasaki, Yutaka

doi:10.1007/s00535-009-0109-8

Cited by 26 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many HCC cases are in an advanced stage or unresectable at the time of diagnosis. Moreover, although unresectable advanced HCC can be treated with hepatic arterial infusion chemotherapy (HAIC) and systemic chemotherapy, the therapeutic effects are limited (1)(2)(3) and the prognosis of advanced cases of HCC is poor.…”

Section: Introductionmentioning

confidence: 99%

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

Hiramine

Uto

Imamura

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Sorafenib is a kinase-targeted drug that has high efficacy for advanced hepatocellular carcinoma (HCC). The aim of the present study was to determine whether sorafenib is more effective than hepatic arterial infusion chemotherapy (HAIC) for HCC. Twenty patients treated with sorafenib (sorafenib group) initiated at 800 mg/day and 45 patients treated with HAIC (HAIC group) for unresectable Child-Pugh A advanced HCC were investigated retrospectively. The treatment effect was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). As a result, the overall response rate was significantly lower in the sorafenib group than in the HAIC group (P=0.03), while the disease control and survival rates did not differ between the two groups. In the sorafenib group, treatment was discontinued in 19 patients, including 12 due to side effects. In subgroups of patients treated with sorafenib, the survival rate was significantly lower in patients (n=11) administered sorafenib for <60 days compared to those (n=9) treated for ≥60 days. A shorter treatment period (<60 days) was an independent risk factor for unfavorable survival [hazard ratio (HR), 3.34; 95% confidence interval (CI), 1.45-7.66 vs. HAIC], while survival in patients treated with sorafenib for ≥60 days did not differ from those treated with HAIC (HR, 0.79; 95% CI, 0.27-2.34). In conclusion, the disease control and survival rates of patients treated with sorafenib for advanced HCC were comparable to such rates in patients treated with HAIC.However, the prognosis was poor when long-term sorafenib treatment was not possible due to side effects, demonstrating the importance of patient selection for sorafenib treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

Hiramine

Uto

Imamura

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Among such drugs, the response rate to CDDP, given as systemic monotherapy, has been reported to be 15% [4] , and multidrug regimens containing this agent may be expected to yield higher response rates. Arterial infusion chemotherapy, which allows higher concentrations of the drug to be achieved inside the tumor and thereby higher antitumor effect, has been reported to yield higher antitumor efficacy than systemic administration, and the reported response rates to arterial infusion regimens containing CDDP range from 41%-61% [5,6] . High efficacy of systemic chemotherapy with CDDP for HCC has not been reported, similarly to various other anticancer drugs.…”

Section: Systemic Chemotherapymentioning

confidence: 99%

“…However, combined regimens containing CDDP and lipiodol have been reported to yield response rates of 15%-57%, while corresponding rates of 45%-73% have been reported for the treatment combined with embolization using gelatin sponge particles. Thus, the response rates of TACE tend to be higher than other chemotherapies [5,6,20,[40][41][42][43][44][45][46][47][48][49][50] (Table 3). Two relevant randomized controlled studies have been reported.…”

Section: Transcatheter Hepatic Arterial Chemoembolizationmentioning

confidence: 99%

Future perspectives on the treatment of hepatocellular carcinoma with cisplatin

Ishikawa¹

2009

WJH

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the commonest primary liver malignancy. Its incidence is increasing worldwide. Surgery, including transplantation resection, is currently the most effective treatment for HCC. However, recurrence rates are high and long-term survival is poor. Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. Cisplatin (CDDP) is a key drug for the standard regimens of various cancers in the respiratory, digestive and genitourinary organs. Recently, several encouraging results have been shown in using CDDP in the treatment of advanced HCC patients. This review examines current knowledge regarding the chemotherapeutic potential of CDDP.

show abstract

“…Although many chemotherapeutic agents, including doxorubicin, epirubicin, mitomycin C, and cisplatin, are used with an oilbased contrast agent (e.g., Lipiodol, Guerbet Japan, Tokyo, Japan), the best choices for first-and second-line drugs for TACE remain uncertain [6][7][8]. With advances in microcatheter and guidewire technology, the tumor-feeding branch can be selected in almost all patients, and the local control effects of TACE have been improved [5].…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Hirakawa

Yamanouchi

Tsuruta

et al. 2017

Interventional Radiology

View full text Add to dashboard Cite

Purpose: This study aimed to retrospectively compare the local control and safety of microballoonoccluded transarterial chemoembolization (B-TACE) using miriplatin (MPT) and of conventional TACE (C-TACE) using epirubicin (EPIR) for hepatocellular carcinoma (HCC).Materials and Methods: Thirty-nine patients (24 men, 15 women; mean age, 73.4 years) were treated using B-TACE with MPT (MPT-B-TACE group). As a historical comparison, 23 patients (13 men, 10 women; mean age, 72.2 years) who were treated using C-TACE with EPIR (EPIR-C-TACE group) were investigated. The therapeutic effect within 2 weeks after treatment was compared between the groups based on the Response Evaluation Criteria in Cancer of the Liver (RECICL), and time to local recurrence was compared based on the Kaplan-Meier method and log-rank tests. The side effects were compared based on the Common Terminology Criteria for Adverse Events (ver. 4.0).Results: No significant differences were noted in patients' characteristics between the groups. The overall incidence of postembolization syndrome was significantly lower in the MPT-B-TACE group than in the EPIR-C-TACE group (p<0.05), but two cases in the MPT-B-TACE group developed grade 2 cholecystitis. Based on the RECICL, the objective response rate, including TE4 and TE3, within 2 weeks after treatment was significantly higher in the MPT-B-TACE group (89.7%) than in the EPIR-C-TACE group (78.3%). Overall, local recurrence was significantly less frequent in the MPT-B-TACE group than in the EPIR-C-TACE group (p=0.02).Conclusion: MPT-B-TACE was associated with a higher objective response rate and lower local recurrence rate than EPIR-C-TACE without a significant increase in adverse effects.

show abstract

Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma

Cited by 26 publications

References 33 publications

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

Future perspectives on the treatment of hepatocellular carcinoma with cisplatin

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Contact Info

Product

Resources

About